TXL

TAXOTERE

Find entries where: TXL

is present as a standalone ligand in 2 entries

as a non-polymer is covalently linked to polymer or other heterogen groups 2 entries

Find related ligands:

Similar Ligands (Stereospecific)

Similar Ligands (Quick Screen)

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	TAXOTERE
Identifiers	n/a
Formula	C₄₃ H₅₃ N O₁₄
Molecular Weight	807.879
Type	NON-POLYMER
Isomeric SMILES	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](c5ccccc5)NC(=O)OC(C)(C)C)O)O)OC(=O)c6ccccc6)(CO4)OC(=O)C)O)C)O
InChI	InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKey	ZDZOTLJHXYCWBA-VCVYQWHSSA-N

Chemical Details
Formal Charge	0
Atom Count	111
Chiral Atom Count	11
Bond Count	116
Aromatic Bond Count	12

Drug Info: DrugBank

DrugBank ID	DB01248
Name	Docetaxel
Groups	approved investigational
Description	Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio
Synonyms	Docetaxel anhydrous N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol TXL Docetaxel Docetaxel trihydrate
Brand Names	Docetaxel Accord Taro-docetaxel Docefrez Docetaxel Kabi Docetaxel Taxotere Docetaxel Mylan Docetaxel Injection USP Docetaxel Winthrop Docetaxel anhydrous PMS-docetaxel Taxespira Docetaxel Non-Alcohol Formula Docetaxel Anhydrous Act Docetaxel 40 mg/ml Docetaxel Teva Docetaxel Injection Docetaxel Teva Pharma
Indication	For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Categories	Agents Causing Muscle Toxicity Antimitotic Agents Antineoplastic Agents Antineoplastic and Immunomodulating Agents BCRP/ABCG2 Substrates Cardiotoxic antineoplastic agents Cyclodecanes Cycloparaffins Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index Cytochrome P-450 CYP3A7 Substrates Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Diterpenes Hepatotoxic Agents Immunosuppressive Agents Microtubule Inhibition Microtubule Inhibitors Mitosis Modulators Myelosuppressive Agents Narrow Therapeutic Index Drugs OATP1B3 substrates P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Taxane Derivatives Taxoids Terpenes Tubulin Modulators
ATC-Code	L01CD02
CAS number	114977-28-5

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Tubulin beta-1 chain	MREIVHIQIGQCGNQIGAKFWEMIGEEHGIDLAGSDRGASALQLERISVY...	unknown
Microtubule-associated protein 2	MADERKDEAKAPHWTSAPLTEASAHSHPPEIKDQGGAGEGLVRSANGFPY...	unknown
Microtubule-associated protein 4	MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETVGKTDYIPL...	unknown
Microtubule-associated protein tau	MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQT...	unknown
Apoptosis regulator Bcl-2	MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFS...	unknown
Nuclear receptor subfamily 1 group I member 2	MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATG...	unknown	binder
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate,inhibitor
Cytochrome P450 3A5	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...	unknown	substrate
Cytochrome P450 3A7	MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNA...	unknown	substrate
Cytochrome P450 1B1	MGTSLSPNDPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSA...	unknown	binder
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Multidrug resistance-associated protein 7	MERLLAQLCGSSAAWPLPLWEGDTTGHCFTQLVLSALPHALLAVLSACYL...	unknown	substrate
Solute carrier organic anion transporter family member 1B3	MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKI...	unknown	substrate
Solute carrier family 22 member 7	MGFEELLEQVGGFGPFQLRNVALLALPRVLLPLHFLLPIFLAAVPAHRCA...	unknown	substrate
ATP-binding cassette sub-family G member 2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	substrate
Canalicular multispecific organic anion transporter 1	MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLH...	unknown	substrate
Multidrug resistance-associated protein 1	MALRGFCSADGSDPLWDWNVTWNTSNPDFTKCFQNTVLVWVPCFYLWACF...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682